

# Marta Laganã

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10198456/publications.pdf>

Version: 2024-02-01

23  
papers

292  
citations

1040056

9  
h-index

888059

17  
g-index

23  
all docs

23  
docs citations

23  
times ranked

294  
citing authors

#	ARTICLE	IF	CITATIONS
1	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. <i>European Journal of Endocrinology</i> , 2022, 186, 25-36.	3.7	41
2	Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2167-e2176.	3.6	3
3	Letter to the Editor From Berruti et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , .	3.6	2
4	Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. <i>Endocrinology</i> , 2022, 163, .	2.8	8
5	Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen. <i>Endocrine</i> , 2022, 77, 438-443.	2.3	7
6	Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 624102.	3.5	7
7	Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2021, 12, 674039.	3.5	5
8	Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor- $\alpha$ . <i>Biomedicines</i> , 2021, 9, 681.	3.2	7
9	Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?. <i>Endocrine</i> , 2021, 74, 475-477.	2.3	4
10	Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy. <i>Endocrine</i> , 2021, 72, 20-23.	2.3	1
11	Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 707346.	2.8	1
12	Treatment With 90Y/177Lu-DOTATOC in Patients With Metastatic Adrenocortical Carcinoma Expressing Somatostatin Receptors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1-e5.	3.6	22
13	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. <i>Frontiers in Oncology</i> , 2020, 10, 588862.	2.8	8
14	Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria. <i>Cancers</i> , 2020, 12, 1395.	3.7	7
15	Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells. <i>Cancers</i> , 2020, 12, 928.	3.7	16
16	Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience. <i>Cancers</i> , 2020, 12, 941.	3.7	38
17	Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study. <i>Cancers</i> , 2020, 12, 969.	3.7	3
18	The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma. <i>Future Oncology</i> , 2020, 16, 3017-3020.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 80-87.	1.4	13
20	Antineoplastic activity of artemisinin in adrenocortical carcinoma. <i>Endocrine</i> , 2019, 66, 425-427.	2.3	3
21	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	3.7	16
22	Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. <i>European Journal of Endocrinology</i> , 2019, 181, 681-689.	3.7	30
23	Immunotherapy failure in adrenocortical cancer: where next?. <i>Endocrine Connections</i> , 2018, 7, E5-E8.	1.9	39